EUVIMEDEUVIMED entdecken
Crossref

Observation of the efficacy and safety of obinutuzumab in the treatment of refractory idiopathic membranous nephropathy

Luyao Li, Sha Wang, Mingming Wei, Qi Zhang, Lin Fang, Xin Fan, Miaomiao Cheng, Chengrui Zhang, Hua Liang, Xiaoyan Xiao, Xiangdong Yang

International Urology and Nephrology · 02.03.2025 · 57 (8) · 2603-2611

DOI: 10.1007/s11255-025-04407-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Urology and Nephrology, online erschienen am 02.03.2025. Verfasst von Luyao Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department Nephrology, Qilu Hospital of Shandong University, No. 107, Wenhua West Road, Lixia District, Jinan City, Shandong Province, China. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: National Natural Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This study analyzed the clinical data of 25 patients with refractory idiopathic membranous nephropathy (RIMN) treated with obinutuzumab, aiming to investigate its efficacy and safety. METHODS: A retrospective study was conducted on patients with RIMN who were treated with obinutuzumab, admitted to the Department of Nephrology at Qilu Hospital of Shandong University and the Affiliated Hospital of Jining Medical College from March 2022 to November 2023. The treatment of obinutuzumab was determined based on the individual patient's specific circumstances. We collected clinical data including urinary protein-to-creatinine ratio (UPCR), serum albumin, creatinine, estimated glomerular filtration rate (eGFR) and circulating anti-phospholipase 2 receptor (PLA2R) antibodies for a minimum of 12 months. The clinical efficacy and safety of obinutuzumab were evaluated in these patients. RESULTS: Among the 25 patients, 19 (76.0%, responders) achieved partial (n = 16) or complete (n = 3) response with obinutuzumab treatment. The median time to achieve partial response was 3.5 months [interquartile range (IQR) 3.0-12.0 months], and 6 patients were unresponsive to the treatment. After treatment with obinutuzumab, 19 of the 21 patients (90.5%) with positive phospholipase 2 receptor (PLA2R) antibodies achieved complete immunological remission (anti-PLA2R antibodies level < 2 RU/mL). The median time to negativity was 6.0 months (IQR 3.0-9.0 months). The two patients who remained positive had PLA2R antibodies titers that decreased below 14 RU/mL and both achieved clinical remission. The renal function remained stable during the follow-up period. No relapse was observed. No severe adverse events related to obinutuzumab were observed. CONCLUSION: Obinutuzumab could effectively relieve proteinuria, stabilize renal function and maintain good safety in patients with RIMN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranousAntibodies, Monoclonal, HumanizedHumansMaleFemaleRetrospective StudiesMiddle AgedAdultTreatment OutcomeAgedReceptors, Phospholipase A2

Stichwörter der Autor:innen

CD20Idiopathic membranous nephropathyObinutuzumabRefractory

Substanzen

Antibodies, Monoclonal, HumanizedobinutuzumabReceptors, Phospholipase A2

Autor:innen und Institutionen

  • Department Nephrology, Qilu Hospital of Shandong University, No. 107, Wenhua West Road, Lixia District, Jinan City, Shandong Province, China.
  • Department Nephrology, Affiliated Hospital of Jining Medical College, No. 89 Guhuai Road, Jining City, Shandong Province, China.
  • Institute of Health and Medical Big Data, Shizhong District, Shandong University, No. 12550, Erhuan South Road, Jinan City, , Shandong Province, China.
  • Department Nephrology, Qilu Hospital of Shandong University, No. 107, Wenhua West Road, Lixia District, Jinan City, Shandong Province, China. xiaoyanxiao2007@163.com.
  • Department Nephrology, Qilu Hospital of Shandong University, No. 107, Wenhua West Road, Lixia District, Jinan City, Shandong Province, China. yxd@email.sdu.edu.cn.

Förderung

  • National Natural Foundation of China

Zitieren

APA

Li, L., Wang, S., Wei, M., Zhang, Q., Fang, L., Fan, X., Cheng, M., Zhang, C., Liang, H., Xiao, X., & Yang, X. (2025). Observation of the efficacy and safety of obinutuzumab in the treatment of refractory idiopathic membranous nephropathy. International Urology and Nephrology, 57(8), 2603-2611. https://doi.org/10.1007/s11255-025-04407-3

Vancouver

Li L, Wang S, Wei M, Zhang Q, Fang L, Fan X, et al. Observation of the efficacy and safety of obinutuzumab in the treatment of refractory idiopathic membranous nephropathy. International Urology and Nephrology. 2025;57(8):2603-2611. doi:10.1007/s11255-025-04407-3

BibTeX
@article{Li2025,
  author = {Li, Luyao and Wang, Sha and Wei, Mingming and Zhang, Qi and Fang, Lin and Fan, Xin and Cheng, Miaomiao and Zhang, Chengrui and Liang, Hua and Xiao, Xiaoyan and Yang, Xiangdong},
  title = {Observation of the efficacy and safety of obinutuzumab in the treatment of refractory idiopathic membranous nephropathy},
  journal = {International Urology and Nephrology},
  year = {2025},
  volume = {57},
  number = {8},
  pages = {2603--2611},
  doi = {10.1007/s11255-025-04407-3}
}
Kostenlos starten →